

The Contribution of the
**BIOPHARMACEUTICAL
INDUSTRY**
in Puerto Rico



Taking Care of Patients in
Puerto Rico & Around the World

ABOUT PIA

PIA'S SCOPE

Research based biopharmaceutical companies operating in Puerto Rico

MISSION

Drive an environment that strengthens Puerto Rico's biopharmaceutical industry's global competitiveness and improves healthcare outcomes for its population.

STRATEGIC PILLARS

Improve competitiveness to retain and attract operations to Puerto Rico.

Improve Patient Outcomes / Healthcare Sustainability Initiative

Drive Social Capital

Build strong networks with key stakeholders

Strengthen PIA's position and capabilities

MEMBERS



OUR AFFILIATE MEMBERS



QUALITY

We lead the manufacturing operations meeting world class quality standards while using advanced technology for **2 of the 10 best-selling drugs in the world and hosting operations from 6 of the 20 largest biopharmaceutical companies on the planet.**

OUR HIGHLY EDUCATED AND TRAINED WORKFORCE

SAFEGUARD THE MEDICINES THAT YOU TAKE HOME FOR YOU AND YOUR LOVED ONES.

75% OF EMPLOYEES WITH COLLEGE DEGREE.



Receive approximately
20 REGULATORY INSPECTIONS
annually from global agencies.



COMMUNITY OUTREACH

WE CARE about the communities where you live.

- **Contributions exceeding \$3 million**, and thousands of volunteer hours contributed towards numerous local non-profit organizations, schools and universities.
- **\$1 MM of donations** to *Fondos Unidos de Puerto Rico* equivalent to 30% of their total income, benefiting those in need.
- **Protecting the environment by recycling**, reducing air pollution, lowering energy consumption, and waste to landfill.



WE CARE about the advancement of Puerto Rico's talent.

- Scholarships, first job experiences, and sponsorship to student organizations.
- Training, educational materials and donations for PK to 12 aiding in the student's journey towards their professional career.



DRIVING IMPACT FOR PATIENTS, COMMUNITIES, AND ECONOMY



30%*

TOTAL MFG REPS 45% OF PR GNP & PHARMA REPS 30% OF MFG



65,000 Jobs



DIRECT

INDIRECT



Assets Base

\$10,700MM



\$450MM

Maint. Cap

2 of top 10 Global Medicines



\$1,150MM

Payroll



\$80,000

Salary



Corporate



= \$1,500mm

Personal



=\$140 mm



> 200 across different municipalities



Patient Support Programs

> 100 with focus on healthcare delivery, early diagnosis, prevention and financial assistance




70% | >120 countries

*Revised 2025

INNOVATION

OVER THE LAST 15 YEARS WE HAVE BROUGHT MORE THAN 500 NEW MEDICINES TO PATIENTS



 Cancer death rates have **declined 23% since 1990.**

Since 2000, more than **500 New Medicines** have been approved by the Food and Drug Administration (FDA) - a record of 45 in 2015

 **Antiretroviral and subsequent innovations preventing almost 900,000 HIV/AIDS deaths.**

PhRMA member companies spent an estimated **\$58.8 Billion** in 2015 to discover and develop new medicines

 Deaths from **heart diseases have declined about 38%** over the past decade.


More than **7,000 Medicines** and treatments are in development globally right now

 **94 to 100% Hepatitis C** cured with latest generation of antiviral therapies.

Roughly **3,500 Compounds** are currently being studied in the United States alone - more than in any region

Source:PhRMA

THE BIOPHARMACEUTICAL RESEARCH AND DEVELOPEMENT PROCESS



Key: IND: Investigational New Drug Application, NDA: New Drug Application, BLA: Biologics License Application

Source:PhRMA

The average R&D cost required to bring a new, FDA approved medicine to patients is estimated to be \$2.6 billion over the past decade (in 2013 dollars), including the cost of the many potential medicines that do not make through to FDA approval.

SAFETY

- **Our innovative medicines** are thoroughly evaluated in clinical trials to assure safety profiles for commercialization.
- **All of our products**, new and established, are constantly monitored for safety throughout the product's life span.
- **Our Industry** diligently monitors and reports any adverse events to the authorities assuring accurate and up-to-date product safety for patients and healthcare professionals.
- **We are committed** to continue investing in patient education, promoting safety and on label use of our medicines, to foster adherence and assure the best health outcomes.

ETHICS & COMPLIANCE

- Our Industry is one of the most regulated industries in the world.
- We operate in a compliant and lawful manner; nothing less is acceptable.
- We are passionate about Patient Care and are guided by the principles of Integrity, Transparency and Legitimate Intent.

